HOME >> MEDICINE >> NEWS
ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

RICHMOND, CALIF. (Monday, May 18, 1998) --- Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX) today reported results from two Phase II studies of its lead anticancer viral therapeutic, ONYX-015, in patients with tumors of the head and neck. In an ongoing Phase II study combining ONYX-015 with standard chemotherapy, the company reported that nine out of ten patients with recurrent tumors have experienced tumor regressions of greater than 50 percent to date, with two patients experiencing complete responses. In addition, the company reported that 30 percent of patients treated with ONYX-015 alone had significant tumor regressions, including two complete regressions in patients with end-stage, treatment-resistant disease.

During a poster session today at the American Society of Clinical Oncology (ASCO) meeting in Los Angeles, Onyx presented interim results from a Phase II trial combining ONYX-015 with Cisplatin and 5-FU, two standard chemotherapeutic agents used in the treatment of head and neck cancers. In addition to the two patients who had complete responses, seven patients experienced between 50 and 95 percent reductions in tumor mass. The one remaining patient has experienced a 40 percent tumor regression. To date, all of the patients continue on treatment with no evidence of disease progression. The average overall response rate with Cisplatin and 5-FU alone is about 35 percent historically in patients with recurrent disease,noted David H. Kirn, M.D., director of clinical research at Onyx.

"We have seen significant tumor regression in the patients treated to date, including some complete responses, and this is a dramatic early finding," Dr. Kirn said. "But we have only evaluated ten patients at this point. While we are encouraged by these initial results, we remain cautiously optimistic."

"Of course, because this is an ongoing study, we do not yet have information regarding durability of responses. We will be able to discuss these findings with gre
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415/ 821-2413
Kureczka/Martin Associates
18-May-1998


Page: 1 2 3

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
5. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
6. Pharmaceuticals and personal care products
7. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
8. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
9. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2018)... ... December 05, 2018 , ... A well-known name in the ... to the masses. Wellbeats , which has delivered on-demand, virtual fitness programming to ... consumer app. Available now in the Apple App Store, the Wellbeats app is ...
(Date:12/5/2018)... Va. (PRWEB) , ... December 05, 2018 , ... Since ... and silicone ruptures. The implants are invisible to the naked eye, ensuring a natural ... properly centered and that there are no signs of implant visibility,” says Dr. Jessica ...
(Date:12/5/2018)... ... December 05, 2018 , ... Domenic ... In this role, he will be responsible for the executive oversight of operations ... conducted an extensive, nationwide search for this position,” Tom Doran, president, HM Insurance ...
(Date:12/5/2018)... FRAMINGHAM, Mass. (PRWEB) , ... December 05, 2018 ... ... data, intelligence, and analytics on the healthcare provider market, announced today that it ... ranks the 500 North American companies with the highest growth in the fields ...
(Date:11/29/2018)... ... 2018 , ... “The total demand for technologies used in drug discovery reached ... at SDi. “We project the market will grow at a healthy annual rate of ... the global population ages.” , This report details market activity in the areas of ...
Breaking Medicine News(10 mins):
(Date:11/29/2018)... ... 29, 2018 , ... Cantata Health, a leading provider of ... care, post-acute care, and long-term care facilities, announced today Elvira Hynds, RHIT has ... Cantata Health’s highly regarded customer support team focusing on initiatives to continuously improve ...
(Date:11/28/2018)... ... November 28, 2018 , ... ... to announce a new partnership with CME Master, a division of HealthMinds Consulting ... with expansion into South East Asia expected soon. This new collaboration will provide ...
(Date:11/28/2018)... ... November 29, 2018 , ... Physician Partners of America welcomes Neil Ellis ... will join Dr. Jorge Leal , as an interventional pain management specialist in ... Toronto, Canada, Dr. Ellis is double board-certified in Anesthesiology and Interventional Pain Medicine by ...
Breaking Medicine Technology:
Cached News: